Indication: Urothelial Cancer

A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with Selected FGFR Gene Alterations

Metastatic or Surgically Unresectable

Sub-indication: Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations

Line of Therapy: Phase 1b: Any number of lines of prior therapy. Phase 2: Progressed after 1 or 2 lines of prior chemotherapy

Drug Study

Principal Investigator: Arash Rezazadeh, M.D.
Norton Cancer Institute

Sponsor: Janssen Research & Development

Learn more at ClinicalTrials.gov

Email for more information: GU-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.